|1.||Phelps, Stephanie J: 1 article (10/2014)|
|2.||Alford, Elizabeth L: 1 article (10/2014)|
|3.||Storgion, Stephanie: 1 article (10/2014)|
|4.||Shelton, Chasity M: 1 article (10/2014)|
|5.||Wheless, James: 1 article (10/2014)|
|6.||Khanfar, Mohammad A: 1 article (11/2010)|
|7.||Melnyk, P: 1 article (11/2010)|
|8.||Debreu-Fontaine, M-A: 1 article (11/2010)|
|9.||Toussaint, M: 1 article (11/2010)|
|10.||Maurice, T: 1 article (11/2010)|
12/01/1975 - "A new syndrome, paradoxical intoxication, has been defined in which high levels of hydantoins, and in one instance carbamazepine, produced an increase in seizures with little or no evidence of intoxication; a decrease in these levels produced an improvement in seizure control. "
11/01/2001 - "The hydantoins were evaluated for possible anticonvulsant activity in the maximal electroshock (MES)- and subcutaneous pentylenetetrazole (ScMet)-induced seizures and for neurotoxicity in the rotorod test in mice and rats."
06/09/2001 - "When hydantoins are combined with BZD, cessation of seizures can be achieved in 94% of the patients compared with 82% when phenobarbital is used alone. "
05/01/1985 - "Selectively substituted hydantoins 1 (15 examples), 4-hydroxy-2-imidazolidinones 2 (13 examples), 2-imidazolones 3 (10 examples), 2-imidazolidinones 4 (four examples), vicinal diamines 5 (two examples), and simple amino acid derivatives 6 (four examples) have been prepared and evaluated in the maximal electroshock seizure (MES), subcutaneous pentylenetetrazole seizure threshold (sc Met), and rotorod (Tox) tests. "
10/01/2014 - "Seizures persisted despite aggressive use of benzodiazepines (intravenous lorazepam; oral clorazepate), barbiturates (i.e., phenobarbital, pentobarbital), and hydantoins. "
06/03/1972 - "The corresponding features were normal in 14 control patients with epilepsy but without hydantoins. "
06/03/1972 - "Various immunological features were measured in 20 patients with epilepsy who had received prolonged treatment with hydantoins. "
06/01/1959 - "[Apropos of neurological complications of the treatment of epilepsy by hydantoins]."
05/01/1952 - "[Neural and endocrine complications in the treatment of epilepsy with hydantoins]."
03/01/1950 - "[Hydantoins in the treatment of epilepsy]."
11/01/1987 - "[Lymphoid neoplasms after therapy with hydantoins. "
04/01/1979 - "Infants exposed in utero to hydantoins should be closely observed for the development of these tumors."
01/01/1977 - "[Hydantoins and lymphoid neoplasms. "
12/13/1975 - "Hydantoins were discontinued in 3 cases but the lymphomas never disappeared spontaneously and only once did tumor progression came to a stillstand. "
11/15/1989 - "A correlation has been established between the ability of barbiturates and hydantoins to promote tumor formation and their ability to induce liver growth, hepatic DNA synthesis and mixed function oxidase activities. "
10/01/1976 - "The fetal hydantoin syndrome is a variable pattern of altered growth and performance which includes unusual facies, distal phalangeal hyoplasia, and other defects occurring in some infants exposed in utero to hydantoins. "
06/01/1981 - "The fetal hydantoin syndrome is a variable pattern of altered growth (pre and postnatal), mental deficiency, unusual facies, distal phalangeal hypoplasia, and other defects occurring in some infants exposed in utero to hydantoins. "
|5.||Prostatic Neoplasms (Prostate Cancer)
|3.||Anticonvulsants (Antiepileptic Drugs)
|7.||Fetal hydantoin syndrome
|9.||Guanidine (Guanidine Nitrate)